Biogen | BIIB - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
AbbVie USD 2.67B 1.71B 2025-12
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Amgen USD 3.92B 2.35B 2025-09
Bayer EUR -1.16B 735M 2025-09
Biogen USD -56M 613.3M 2025-12
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Incyte USD 389.94M 92.37M 2025-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09